# United Arab Emirates Chemicals Export Opportunities (HS 28-38)

![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp)

> Yugalinks sector export playbook

Explore United Arab Emirates HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities.

## Overview

- Exporter: United Arab Emirates (ARE)
- Sector: Chemicals
- HS chapters: HS 28-38
- Latest trade year: 2024
- Sector exports: $802.6M
- Products: 37
- Buyer markets: 26
- Average CAGR: +21.8%
- Global sector size: $689.8B

## Product portfolio

| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $294.1B | $19.7M | $111.8B | +15.3% | 18 | +0.0% |
| HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $138.5B | $1.3M | $54.8B | +13.0% | 10 | +0.0% |
| HS 300220 - Vaccines: for human medicine | $25.9B | $484.7K | $21.6B | -15.0% | 5 | +0.0% |
| HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $24.4B | $349.0K | $14.7B | +25.7% | 7 | +0.0% |
| HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $19.9B | $18.0M | $13.7B | +58.3% | 5 | +0.1% |
| HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $25.3B | $96.9K | $13.6B | +0.9% | 4 | +0.0% |
| HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $13.4B | $15.1M | $12.3B | +54.6% | 5 | +0.1% |
| HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $11.8B | $179.2K | $11.7B | +4.3% | 2 | +0.0% |
| HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $11.9B | $23.8K | $7.4B | +6.0% | 2 | +0.0% |
| HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $11.3B | $23.1K | $7.3B | +287.2% | 2 | +0.0% |
| HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $15.1B | $42.5K | $6.3B | +19.7% | 3 | +0.0% |
| HS 290243 - Cyclic hydrocarbons: p-xylene | $8.5B | $57.8M | $6.2B | +58.4% | 1 | +0.6% |
| HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $4.4B | $18.6K | $6.0B | -2.7% | 1 | +0.0% |
| HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $14.9B | $9.7M | $5.9B | +42.4% | 2 | +0.1% |
| HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $6.9B | $3.3 | $5.0B | -36.1% | 1 | +0.0% |
| HS 381800 - Chemical elements: doped for use in electronics, in the form of discs, wafers or similar forms: chemical compounds doped for use in electronics | $6.6B | $4.8K | $4.9B | -9.3% | 3 | +0.0% |
| HS 293379 - Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) | $4.2B | $777.0 | $4.8B | -4.8% | 1 | +0.0% |
| HS 290110 - Acyclic hydrocarbons: saturated | $2.0B | $3.7K | $3.8B | -38.1% | 1 | +0.0% |
| HS 381512 - Catalysts, supported: reaction initiators, reaction accelerators and catalytic preparations, with precious metal or precious metal compounds as the active substance, n.e.c. or included | $4.5B | $543.2K | $3.8B | +111.7% | 2 | +0.0% |
| HS 290220 - Cyclic hydrocarbons: benzene | $4.1B | $1.6K | $3.5B | -57.9% | 1 | +0.0% |
| HS 281820 - Aluminium oxide: other than artificial corundum | $3.5B | $1.2K | $3.4B | +8.7% | 2 | +0.0% |
| HS 330300 - Perfumes and toilet waters | $6.6B | $640.5M | $3.2B | +22.0% | 2 | +6.3% |
| HS 290121 - Acyclic hydrocarbons: unsaturated, ethylene | $1.8B | $2.6M | $2.4B | -7.1% | 1 | +0.1% |
| HS 290531 - Alcohols: acyclic, diols: ethylene glycol (ethanediol) | $3.2B | $6.3M | $2.2B | +53.2% | 1 | +0.2% |
| HS 290919 - Ethers: acyclic, and their halogenated, sulphonated, nitrated or nitrosated derivatives, other than diethyl ether | $1.5B | $227.8K | $2.1B | -6.1% | 1 | +0.0% |
| HS 300420 - Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $1.1K | $2.0B | -3.9% | 1 | +0.0% |
| HS 293299 - Heterocyclic compounds: with oxygen hetero-atom(s) only, no lactones or unfused furan rings (hydrogenated or not) in the structure, other than isosafrole, 1-(1,3-benzodiaxol-5-yl) propan-2-one, piperonal, safrole, tetrahydrocannabinols (all isomers) | $2.4B | $8.8K | $2.0B | -1.9% | 1 | +0.0% |
| HS 382319 - Industrial monocarboxylic fatty acids: acid oils from refining: (other than stearic acid, oleic acid or tall oil fatty acids) | $1.3B | $850.8K | $1.9B | +27.4% | 1 | +0.1% |
| HS 290122 - Acyclic hydrocarbons: unsaturated, propene (propylene) | $1.6B | $25.8M | $1.8B | +19.2% | 1 | +1.3% |
| HS 370790 - Photographic goods: chemical preparations other than sensitised emulsions, put up in measured portions or put up for retail sale in a form ready for use | $2.2B | $11.1K | $1.8B | -12.1% | 1 | +0.0% |
| HS 284420 - Uranium: enriched in U235, plutonium, their compounds, alloys dispersions (including cermets), ceramic products and mixtures containing uranium enriched in U235, plutonium or compounds of these products | $4.9B | $164.6 | $1.7B | +19.4% | 1 | +0.0% |
| HS 284390 - Inorganic or organic compounds: of precious metals (excluding gold and silver), whether or not chemically defined, amalgams of precious metals | $892.9M | $2.5K | $1.7B | +10.6% | 1 | +0.0% |
| HS 300670 - Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | $1.2B | $1.9K | $1.4B | -4.1% | 1 | +0.0% |
| HS 284410 - Uranium: natural uranium and its compounds, alloys, dispersions (including cermets), ceramic products and mixtures containing natural uranium or natural uranium compounds | $1.6B | $64.8 | $1.4B | -2.1% | 1 | +0.0% |
| HS 291736 - Acids: aromatic polycarboxylic acids: terephthalic acid and its salts | $1.6B | $1.2 | $1.4B | -33.0% | 1 | +0.0% |
| HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.2B | $8.9K | $1.4B | +17.8% | 1 | +0.0% |
| HS 310530 - Fertilizers, mineral or chemical: diammonium hydrogenorthophosphate (diammonium phosphate) | $2.7B | $2.9M | $1.3B | +2.2% | 1 | +0.1% |

## Best markets

- USA, Puerto Rico and US Virgin Islands (USA): $94.8B calculated opportunity across 16 products.
- China (CHN): $46.9B calculated opportunity across 16 products.
- Germany (DEU): $38.7B calculated opportunity across 12 products.
- Switzerland, Liechtenstein (CHE): $36.6B calculated opportunity across 4 products.
- Belgium (BEL): $22.8B calculated opportunity across 4 products.
- Netherlands (NLD): $19.6B calculated opportunity across 5 products.
- United Kingdom (GBR): $11.1B calculated opportunity across 5 products.
- Canada (CAN): $10.0B calculated opportunity across 5 products.
- Italy (ITA): $9.8B calculated opportunity across 2 products.
- Slovenia (SVN): $9.7B calculated opportunity across 1 products.
- France (FRA): $9.3B calculated opportunity across 4 products.
- Spain (ESP): $6.5B calculated opportunity across 2 products.

## Growth stars

- HS 300214: +287.2% average CAGR, $7.3B calculated opportunity.
- HS 381512: +111.7% average CAGR, $3.8B calculated opportunity.
- HS 290243: +58.4% average CAGR, $6.2B calculated opportunity.
- HS 382499: +58.3% average CAGR, $13.7B calculated opportunity.
- HS 382600: +54.6% average CAGR, $12.3B calculated opportunity.
- HS 290531: +53.2% average CAGR, $2.2B calculated opportunity.
- HS 330499: +42.4% average CAGR, $5.9B calculated opportunity.
- HS 382319: +27.4% average CAGR, $1.9B calculated opportunity.
- HS 300439: +25.7% average CAGR, $14.7B calculated opportunity.
- HS 330300: +22.0% average CAGR, $3.2B calculated opportunity.

## Diversification opportunities

- HS 300490: 18 buyer markets, $111.8B calculated opportunity.
- HS 300215: 10 buyer markets, $54.8B calculated opportunity.
- HS 300439: 7 buyer markets, $14.7B calculated opportunity.
- HS 300220: 5 buyer markets, $21.6B calculated opportunity.
- HS 382499: 5 buyer markets, $13.7B calculated opportunity.
- HS 382600: 5 buyer markets, $12.3B calculated opportunity.
- HS 300212: 4 buyer markets, $13.6B calculated opportunity.
- HS 382200: 3 buyer markets, $6.3B calculated opportunity.
- HS 381800: 3 buyer markets, $4.9B calculated opportunity.
- HS 293359: 2 buyer markets, $11.7B calculated opportunity.

## Method

Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology).

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.